Supplementary Table 1.　Stratification Analysis for Associations between *CYP1B1* SNPs and PCa Risk

Variables	rs1056836 (cases/controls)		OR (95%CI)[a]	P[a]	P[b]	rs9341266 (cases/controls)		OR (95%CI)[a]	P[a]	P[b]	rs162549 (cases/controls)		OR (95%CI)[a]	P[a]	P[b]	rs10916 (cases/controls)		OR (95%CI)[a]	P[a]	P[b]
	CG/GG	CC				AG/AA	GG				AT/AA	TT				GT/GG	TT			
Age																				
≤ 69	153/181	361/375	0.88 (0.68-1.15)	0.353	0.737	125/136	389/420	0.99 (0.75-1.31)	0.959	0.380	113/107	401/449	1.15 (0.85-1.55)	0.368	0.068	107/104	407/452	1.16 (0.86-1.57)	0.344	0.849
> 69	134/166	367/330	0.72 (0.55-0.95)	0.019		116/100	385/396	1.19 (0.88-1.60)	0.270		115/134	386/362	0.80 (0.60-1.07)	0.130		100/92	401/404	1.09 (0.80-1.50)	0.576	
Smoking status																				
Never	114/131	292/281	0.85 (0.63-1.14)	0.272	0.712	93/92	313/320	1.03 (0.74-1.44)	0.844	0.752	91/96	315/316	0.93 (0.67-1.30)	0.677	0.848	72/82	334/330	0.87 (0.61-1.24)	0.832	0.069
Ever	173/216	436/424	**0.77 (0.61-0.98)**	**0.036**		148/144	461/496	1.11 (0.85-1.44)	0.443		137/145	472/495	0.97 (0.75-1.27)	0.845		135/114	474/526	**1.36 (1.00-1.75)**	**0.048**	
Gleason score																				
≤ 7(3+4)	89/347	228/705	0.79 (0.60-1.04)	0.096	0.969	80/236	237/816	1.16 (0.87-1.56)	0.310	0.820	68/241	249/811	0.91 (0.67-1.23)	0.533	0.769	75/196	242/856	**1.37 (1.01-1.85)**	**0.044**	0.258
≥ 7(4+3)	171/347	435/705	**0.80 (0.64-0.99)**	**0.041**		148/236	458/816	1.12 (0.88-1.41)	0.359		136/241	470/811	0.96 (0.75-1.22)	0.713		120/196	486/856	1.08 (0.84-1.40)	0.537	
Stage of disease																				
I /II	129/347	310/705	0.85 (0.66-1.08)	0.179	0.515	114/236	325/816	1.20 (0.93-1.55)	0.169	0.400	94/241	345/811	0.90 (0.69-1.18)	0.462	0.650	104/196	335/856	**1.36 (1.04-1.79)**	**0.024**	0.107
III /IV	135/347	363/705	**0.75 (0.59-0.95)**	**0.017**		115/236	383/816	1.04 (0.81-1.34)	0.760		114/241	384/811	0.98 (0.76-1.27)	0.897		96/196	224/856	1.05 (0.80-1.37)	0.744	

[a] Adjusted for age and smoking status.

[b]*P* value for homogeneity test.

The results were in bold if *P* < 0.05.

(Continued)

Supplementary Table 1.   Stratification Analysis for Associations between *CYP1B1* SNPs and PCa Risk

Variables	*rs162562* (cases/controls)		OR (95%CI)[a]	P^a	P^b	rs2551188 (cases/controls)		OR(95%CI)[a]	P^a	P^b	rs9341250 (cases/controls)		OR (95%CI)[a]	P^a	P^b	rs1056827 (cases/controls)		OR (95%CI)[a]	P^a	P^b
	AC/CC	AA				CT/TT	CC				AC/AA	CC				AC/AA	CC			
Age																				
≤69	166/188	348/368	0.93 (0.81-1.05)	0.547	0.737	237/278	277/278	0.88 (0.69-1.12)	0.309	0.082	33/39	481/517	0.91 (0.56-1.48)	0.706	0.902	160/185	354/371	0.90 (0.70-1.17)	0.434	0.691
>69	154/153	347/343	1.01 (0.77-1.32)	0.969		237/216	264/280	1.17 (0.91-1.51)	0.213		27/28	474/468	0.97 (0.56-1.67)	0.904		187/188	314/308	0.99 (0.77-1.28)	0.947	
Smoking status																				
Never	135/132	271/280	1.06 (0.79-1.42)	0.686	0.404	180/180	226/232	1.04 (0.79-1.37)	0.897	0.750	24/25	382/387	0.97 (0.54-1.73)	0.918	0.824	150/152	256/260	1.02 (0.77-1.35)	0.906	0.594
Ever	185/209	424/431	0.91 (0.71-1.15)	0.418		294/314	315/326	0.99 (0.79-1.24)	0.947		36/42	573/598	0.93 (0.59-1.47)	0.755		197/221	412/419	0.90 (0.71-1.14)	0.400	
Gleason score																				
≤ 7(3+4)	106/341	211/711	1.05 (0.80-1.37)	0.728	0.418	161/494	156/558	1.18 (0.92-1.52)	0.201	0.173	23/67	294/985	1.20 (0.73-1.96)	0.471	0.311	107/373	210/679	0.92 (0.71-1.20)	0.553	0.913
≥ 7(4+3)	184/341	422/711	0.91 (0.74-1.14)	0.416		274/494	332/558	0.94 (0.77-1.15)	0.557		32/67	574/985	0.83 (0.54-1.29)	0.410		202/373	404/679	0.91 (0.74-1.13)	0.388	
Stage of disease																				
I / II	144/341	295/711	1.02 (0.81-1.30)	0.857	0.532	224/494	215/558	1.19 (0.95-1.49)	0.126	0.058	30/67	409/985	1.10 (0.70-1.72)	0.671	0.322	139/373	127/679	0.91 (0.64-1.13)	0.159	0.145
III /IV	152/341	346/711	0.92 (0.73-1.16)	0.473		217/494	281/558	0.88 (0.71-1.09)	0.246		25/67	473/985	0.79 (0.49-1.28)	0.339		174/373	131/679	0.98 (0.65-1.32)	0.547	

[a] Adjusted for age and smoking status.
[b]*P* value for homogeneity test.
The results were in bold if *P* < 0.05.

Supplementary Table 2. Clinicopathological Characteristics of the Subset of Pca Patients who Received RP

Variables	BCR	Non-BCR	P^a	HR (95% CI)	P
Telomere Length					
By median					
Longer	47 (47.0)	171 (47.5)	0.340	1.00	
Shorter	53 (53.0)	155 (52.5)		1.26 (0.85-1.87)	0.243
By tertile					
First	36 (36.0)	106 (32.5)	0.112	1.00	
Second	40 (40.0)	106 (32.5)		1.00 (0.64-1.58)	0.989
Third	24 (24.0)	114 (35.0)		0.65 (0.39-1.08)	0.097
By quartile					
First	30 (30.0)	77 (23.6)	0.608	1.00	
Second	26 (26.0)	87 (26.7)		0.86 (0.51-1.46)	0.578
Third	23 (23.0)	81 (24.8)		0.73 (0.43-1.26)	0.261
Fourth	21 (21.0)	81 (24.8)		0.73 (0.42-1.28)	0.269

RP: radical prostatectomy; BCR: Biochemical recurrence

[a]A two-sided Chi-square test was used.

Supplementary Table 3.   FPRP Values for Associations between PCa Risk and CYP1B1 SNPs

SNP	Statistical power	Prior probability				
		0.25	0.1	0.01	0.001	0.0001
rs1056836						
CG vs. CC	0.977	0.119	0.188	0.617	0.978	0.998
CG/GG vs. CC	0.885	0.135	0.167	0.737	0.981	0.998
Ever smoker	0.825	0.149	0.344	0.852	0.983	0.998
Gleason score $\geq$ 7 (4+3)	0.577	0.186	0.407	0.883	0.987	0.999
Stage III/IV	0.835	0.066	0.176	0.701	0.959	0.996
rs10916						
Ever smoker	0.839	0.164	0.370	0.866	0.985	0.998
Gleason score $\leq$ 7(4+3)	0.754	0.164	0.371	0.866	0.985	0.998
Stage I/II	0.777	0.093	0.236	0.773	0.972	0.997

The results in false-positive report probability analysis were in bold, if the prior probability < 0.2